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Abstract
In the last two decades it has become apparent that thrombin
has many extravascular effects that are mediated by a family
of protease-activated receptors (PARs). PAR-1, -3 and -4 are
activated via cleavage by thrombin. The importance of extra-
vascular thrombin in modulating ischemic, hemorrhagic and
traumatic injury in brain has recently become clear. Thus,
in vitro, thrombin at low concentration protects neurons and
astrocytes from cell death caused by a number of different
insults. In vivo, pretreating the brain with a low dose of
thrombin (thrombin preconditioning), attenuates the brain
injury induced by a large dose of thrombin, an intracerebral
hemorrhage or by focal cerebral ischemia. Thrombin may also
be an important mediator of ischemic preconditioning. In
contrast, high doses of thrombin kill neurons and astrocytes
in vitro and cause disruption of the blood–brain barrier, brain
edema and seizures in vivo. This review examines the role of
thrombin in brain injury and the molecular mechanisms and
signaling cascades involved.
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There has been much interest in the role that serine proteases
play in brain injury. Much of this has focused on tissue
plasminogen activator (tPA) because of its use as a
therapeutic agent for ischemic stroke (The NINDS rt-PA
stroke study group 1995) and because of evidence that
suggests that endogenous tPAwithin the brain may modulate
different forms of brain injury (Gingrich and Traynelis 2000).
However, there is a growing body of work indicating that
another serine protease, thrombin, also plays an important
role in modulating brain injury processes and this is the focus
of the current review.
Thrombin, a serine protease generated by the cleavage of
prothrombin, is an essential component of the coagulation
cascade. It is produced in the brain either immediately after a
cerebral hemorrhage (either primary or secondary to brain
trauma) or after the blood–brain barrier (BBB) breakdown
that occurs following many kinds of brain injury (Lee et al.
1996a). Evidence, both in vivo (Nishino et al. 1993; Lee
et al. 1996b; Lee et al. 1997a,b; Xi et al. 1998) and in vitro
(Vaughan et al. 1995; Striggow et al. 2000; Jiang et al.
2002a), indicates that high concentrations (more than
500 nM) of thrombin within the brain parenchyma can be
deleterious. Our recent studies have demonstrated that
thrombin is responsible for early brain edema formation
following intracerebral hemorrhage (ICH) and contributes to
ischemic brain injury (Lee et al. 1996b; Striggow et al.
2000; Xi et al. 2002). However, thrombin at very low
concentrations (from 50 pM to 100 nM) is neuroprotective
(Vaughan et al. 1995; Xi et al. 1999; Masada et al. 2000;
Striggow et al. 2000; Xi et al. 2000). This review examines
the role of thrombin in brain injury and the mechanisms and
pathways involved.
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The dichotomy in the cerebral effects of thrombin may
reflect its multiple actions. Thus, thrombin enhances the
synthesis and secretion of nerve growth factor in glial cells,
modulates neurite outgrowth, reverses process-bearing stel-
late astrocytes to epithelial-like astrocytes, stimulates astro-
cyte proliferation and modulates the cytoskeleton of
endothelial cells (Grand et al. 1996). It also potentiates
NMDA receptor function (Gingrich et al. 2000) and activates
rodent microglia in vitro (Moller et al. 2000), factors that
may enhance brain injury. Furthermore, a combined intra-
cerebral injection of thrombin and tissue-type plasminogen
activator, causes more brain injury than injection of either
compound alone (Figueroa et al. 1998). An understanding of
these multiple actions of thrombin may lead to potentially
novel therapeutic strategies for brain injury, particularly if the
thrombin-activated signaling pathways can be elucidated.
This might allow selective inhibition of deleterious pathways
and activation of protective pathways.
Thrombin in the brain after injury
Prothrombin, which is synthesized primarily in the liver, is
present in plasma at micromolar levels. Activation of either
the intrinsic or extrinsic coagulation cascade results in the
production of Factor Xa, which cleaves prothrombin to
thrombin. Upon clotting, 1 mL of whole blood can produce
about 1–2 nmols of thrombin. Thus, brain injuries that result
in the entry of blood into brain, such as a primary
intracerebral hemorrhage and brain trauma, result in the
immediate production of large amounts of thrombin from
cleavage of the prothrombin in the blood. Although it should
be noted that the precise perihematomal concentrations have
not been measured.
Many ischemic and traumatic brain injuries are associated
with BBB disruption without hemorrhage. Evidence suggests
that thrombin levels are increased in such tissue (Xi et al.
2002). Because the BBB becomes permeable to large
molecular weight proteins in such injuries, this production
of thrombin may result from the entry of elements of the
coagulation cascade, including prothrombin, from blood.
However, the brain may also be a source of prothrombin.
In vitro studies have shown that prothrombin mRNA is
expressed in the cells of the nervous system (Dihanich et al.
1991). Prothrombin mRNA in the brain is up-regulated after
cerebral ischemia and spinal cord injury (Citron et al. 2000;
Riek-Burchardt et al. 2002; Xi et al. 2002). These results
suggest that thrombin may be formed and cause brain injury
even if the BBB is intact, particularly because the mRNA for
Factor X is present in brain (Shikamoto and Morita 1999).
Whether Factor X can be activated in the brain without the
entry of other coagulation factors from blood is unknown.
Current information on the presence within brain of elements
of the coagulation cascade and their inhibitors is depicted in
Fig. 1.
Thrombin receptors in the brain
Although thrombin has a vital role in hemostasis through
cleavage of fibrinogen to fibrin, other important cellular
activities of thrombin, such as p44/42 mitogen-activated
protein kinases (MAPKs) activation, appear to be receptor
mediated. Carney and Cunningham first identified thrombin
receptors in 1978 and the first receptor was cloned in 1991 (Vu
et al. 1991). Thrombin receptors are seven transmembrane
G protein-coupled receptors that are activated by proteolytic
cleavage rather than by ligand binding. Three protease-
activated receptors (PARs), PAR-1, -3 and -4, can be activated
by thrombin, whereas PAR-2 is activated by trypsin and mast
cell tryptase (Coughlin 2000). Thrombin receptor mRNA
expression is found in neurons and astrocytes (Weinstein et al.
1995), and there is functional evidence for the presence of
thrombin receptors on both cell types (Gingrich and Traynelis
2000; Ubl et al. 2000; Wang et al. 2002).
PAR-1, -3 and -4 are linked to a wide variety of
intracellular signaling cascades (Coughlin 2000). Thus, for
example, PAR-1 can couple to members of the G12/13, Gq and
Gi families, and dependent on which G protein is coupled
it may regulate Rho, inositol 1,4,5-triphosphate (IP3) (and
Fig. 1 Elements of thrombin signaling and
coagulation cascade, present in the brain
with an intact blood–brain barrier (open
boxes) and those that may enter brain
parenchyma after blood–brain barrier dis-
ruption (gray boxes).
4 G. Xi et al.
 2003 International Society for Neurochemistry, Journal of Neurochemistry, 84, 3–9
thus Ca2+), diacylglycerol, adenylate cyclase and a number
of other pathways (Coughlin 2000).
Thrombin inhibitors in the brain
Understanding the effects of thrombin after brain injury also
requires knowledge of endogenous thrombin inhibitors. In
the brain, the effects of thrombin are modulated by serine
protease inhibitors (serpins) and other thrombin inhibitors
such as thrombomodulin. Serpins are a superfamily of
proteins including anti-thrombin III (AT III), a1-protease
inhibitor, plasminogen activator inhibitor-1 (PAI-1), protease
nexin-1 (PN-1), heparin cofactor II and colligin. In the
normal brain parenchyma, of the serpins that inhibit throm-
bin, only PN-1 and PAI-1 appear to be present with PN-1
being found in high concentrations. In addition, colligin is an
inducible serpin in the brain (Xi et al. 2000).
PN-1, also known as glia-derived nexin, is localized
around blood vessels and may act as the main thrombin
inhibitor in the brain (Guenther et al. 1985; Stone et al.
1987). Despite its name, there is evidence that PN-1
expression is not limited to astrocytes as PN-1 mRNA has
also been detected in neurons using in situ hybridization.
PN-1 can modulate the mitogenic effects of thrombin and
promote stellation of astrocytes (Cavanaugh et al. 1990).
Delayed PN-1 up-regulation in the brain has been observed
after cerebral ischemia and peripheral nerve lesion. PAI-1 is
an inhibitor of urokinase (uPA) and tPA, but it can also
inhibit thrombin (Mutch et al. 2001). PAI-1 may also inhibit
thrombin production by inhibiting the cleavage of prothrom-
bin to thrombin by activated factor X. Compared with PN-1,
PAI-1 is a poor inhibitor of thrombin (second order rate
constant 0.01 · 105 M)1s)1 vs. 15 · 105 M)1s)1 for PN-1).
However, as with PN-1 and AT III, addition of a cofactor
increases its effectiveness (second order rate constant
2.2 · 105 M)1s)1 in the presence of vitronectin) (Stone et al.
1987; Preissner et al. 1996).
Colligin, a collagen-binding serpin, is also called heat shock
protein 47. Colligin localizes in the lumen of the endoplasmic
reticulum and is induced in microglia and astrocytes after
cerebral ischemia, subarachnoid hemorrhage and an intracer-
ebral infusion of thrombin (Xi et al. 2000). The effects of
colligin against thrombin may occur through restructuring the
extracellular matrix rather than direct protease inhibition.
Thrombomodulin (TM), an important thrombin-binding pro-
tein, is detected in endothelial cells and astrocytes (Pindon
et al. 2000). TM inhibits thrombin by forming a TM–thrombin
complex that then induces the activation of protein C, an anti-
coagulatant. TM gene expression is increased in astrocytes
after injury and this up-regulation might be mediated by
thrombin via PAR-1 (Pindon et al. 2000). Sarker et al.
reported that either a recombinant TM or a minimum
functional domain of TM reduces thrombin-induced neuronal
cell death (Sarker et al. 1999).
Thrombin-induced brain tolerance
Low concentrations of thrombin are neuroprotective in vitro
and in vivo. In vitro studies have shown that thrombin
protects rat primary astrocytes from hypoglycemia or oxida-
tive stress induced cell death. Thrombin also protects rat
primary hippocampal neurons from cell death produced by
hypoglycemia, hypoxia or growth supplement deprivation
(Vaughan et al. 1995; Striggow et al. 2000). In addition,
thrombin attenuates neuronal cell death and modulates
astrocyte reactivity induced by b-amyloid in vitro. The effect
of thrombin on both neurons and astrocytes is mimicked by
thrombin receptor-activating peptide and inhibited by two
potent thrombin inhibitors, hirudin and protease nexin-1
(Pike et al. 1996). Furthermore, thrombin pretreatment
prevents cell damage induced by a large dose of thrombin
in vitro (Jiang et al. 2002a).
In vivo studies have shown that intracerebral infusion of
a low dose of thrombin (thrombin preconditioning; TPC)
reduces the brain injury that follows a subsequent intracer-
ebral infusion of a high dose of thrombin, an intracerebral
hemorrhage or cerebral ischemia (Xi et al. 1999; Masada
et al. 2000; Xi et al. 2000). Thrombin pretreatment signifi-
cantly attenuated the brain edema which normally follows
the infusion of a large dose of thrombin. This effect was
abolished by a thrombin inhibitor, hirudin (Xi et al. 1999).
TPC may also be an important component of ischemic
preconditioning as the thrombin inhibitor, hirudin, can block
ischemic brain tolerance (Striggow et al. 2000).
Although the precise mechanisms of thrombin-induced
brain tolerance to hemorrhagic and ischemic stroke are not
known, activation of thrombin receptors, up-regulation of
thrombin inhibitors and heat shock proteins in the brain may
be associated with the induced tolerance (Xi et al. 1999; Xi
et al. 2000; Hua et al. 2002; Jiang et al. 2002a).
The majority of cellular functions influenced by thrombin
are mediated by thrombin receptors (PAR-1, -3 and -4) under
normal conditions (Coughlin 2000). Thrombin receptor
activation is involved in the protection induced by TPC as
the effect is mimicked by a thrombin receptor agonist and
suppressed by a thrombin receptor antagonist both in vivo
and in vitro (Jiang et al. 2002a). Striggow et al. also found
that a thrombin receptor-activating peptide mimicks the
effects of a low concentration of thrombin (50 pM) in
reducing ischemic neuronal injury in vitro (Striggow et al.
2000). Activation of thrombin receptor is associated with
neuroprotection induced by thrombin (Jiang et al. 2002a).
Prior activation of thrombin receptor by either thrombin
receptor-activating peptide (TRAP) or by thrombin resulted
in full protection of thrombin receptor mRNA levels under
hypoxic conditions (Landau et al. 2000).
Endogenous thrombin inhibitors such as PAI-1 may be
responsible for thrombin-induced brain protection. PAI-1
content is increased after intracerebral infusion of thrombin
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in a dose-dependent manner, as well as after intracerebral
hemorrhage and cerebral ischemia. Hirudin blocked the
up-regulation of PAI-1 after ICH indicating a role for
thrombin (Ahn et al. 1999; Hua et al. 2002). PAI-1 appears
to be neuroprotective as it reduces NMDA-induced neuro-
toxicity (Buisson et al. 1998) and ischemic infarct volume is
increased in PAI-1 knockout mice (Nagai et al. 1999).
However, the protective effect conferred by PAI-1 may not
be a result of its action against thrombin alone because PAI-1
is also an inhibitor of tPA.
Induction of heat shock proteins (HSPs) may also
contribute to thrombin-induced brain tolerance. HSP27 and
HSP47 are both up-regulated after thrombin treatment (Xi
et al. 1999, 2000). In vivo, TPC-induced brain tolerance
against thrombin-induced brain edema appears to peak about
seven days after thrombin treatment. This time delay for
tolerance induction suggests that new protein synthesis is
required. The timecourse of HSP27 (western blot) also found
peak levels about seven days after TPC. The close temporal
relationship between HSP27 expression and thrombin-
induced tolerance suggests that there may be a causal
relationship. HSP27 can modulate the cytoskeleton by
altering actin dynamics. It has been suggested that HSP27
protects against heat shock and oxidative stress through
stabilization of actin filaments. Reorganization of the actin
cytoskeleton may alter cell swelling following brain injuries
(Xi et al. 1999). In addition, HSP27 may have other
protective effects, including acting as a molecular chaperon
and increasing levels of the antioxidant glutathione (Sharp
et al. 1999).
The mechanisms by which HSP47 (colligin) up-regulation
might be involved in attenuating ICH-induced brain edema
are unclear. Colligin can inhibit thrombin but it is found in
the endoplasmic reticulum. Instead, the effects of colligin
against thrombin-induced injury may involve restructuring of
the extracellular matrix rather than direct protease inhibition.
Colligin is an essential factor for procollagen formation in
the endoplasmic reticulum and prevents abnormal procolla-
gen secretion. Procollagen is secreted to the extracellular
space and forms collagen, a primary component of extracel-
lular matrix. The extracellular matrix has been suggested as
an important factor that regulates thrombin toxicity. In vitro,
cells attached to an extracellular matrix are much less
susceptible to thrombin-induced death (Cunningham and
Donovan 1997).
Thrombin-induced brain injury
Although low concentrations of thrombin protect the brain
from various kinds of injury, high concentrations cause brain
damage. Thus, evidence indicates that thrombin plays an
important role in inducing brain injury after intracerebral
hemorrhage (Lee et al. 1996b; Xi et al. 1998). The brain
edema induced by intracerebral infusion of 100 lL of blood
in the rat is roughly equivalent to that induced by the infusion
of 5 U of thrombin. Considering that the prothrombin in
100 lL of blood could generate about 30 U of thrombin, it
appears that there is sufficient thrombin in a hematoma to
induce brain injury. In addition, hirudin and N-a-(2-naph-
thalenesulfonylglycyl)-4-amidino-DL-phenylalaninepiperi-
dide (a-NAPAP), two thrombin inhibitors, both inhibit
edema formation in a rat intracerebral hemorrhage model
(Lee et al. 1996a,b; Striggow et al. 2000).
There is evidence that thrombin also mediates brain injury
in human ICH, with perihematomal brain edema being less
after systemic treatment with argatroban, a thrombin inhibitor
(Hamada et al. 2000). Drug administration was only started
24 h after the hemorrhage to prevent rebleeding. Thus,
although thrombin is produced immediately as blood clots
following ICH, some thrombin appears to be still present for
at least 24 h. Some of thrombin produced during coagulation
may remain within the hematoma where it is associated with
fibrin, and may be released slowly into the surrounding brain
(Mutch et al. 2001). Alternately, prothrombin from plasma
may enter the brain as a result of BBB disruption and be
converted into thrombin. Thrombin may also contribute to
brain injury in subarachnoid hemorrhage (SAH). Thrombin
activity is increased in cerebrospinal fluid after SAH and is
correlated with the degree of SAH and the development of
vasospasm (Kasuya et al. 1998).
There is growing direct evidence suggesting that thrombin
may also play crucial roles in brain injury after cerebral
ischemia. Thrombin activity is increased in the ischemic core
zone and prothrombin gene expression is also up-regulated
several hours after middle cerebral artery occlusion in the rat
(Xi et al. 2002). Intraventricular infusion of hirudin increases
the survival of hippocampal CA1 neurons after global
cerebral ischemia in gerbils (Striggow et al. 2000). Throm-
bin receptors are markedly up-regulated in hippocampus after
oxygen/glucose deprivation in vitro (Striggow et al. 2001).
Systemic administration of thrombin inhibitors has been
shown effective in experimental cerebral ischemia. Argatro-
ban, a specific thrombin inhibitor, reduces infarction volume,
improves neurological outcome and extends the therapeutic
window for tPA treatment in a rat embolic model (Morris
et al. 2001). In addition, argatroban reduces neurodegener-
ation and brain edema following bilateral common carotid
artery occlusion with reperfusion in gerbils (Ohyama et al.
2001). Two other thrombin inhibitors, melagatran and
inogatran, reduce the cortical infarction induced by photo-
chemical reaction in rats (Mikulski et al. 2001). The extent to
which ischemic protection with systemic thrombin inhibitors
reflects vascular or parenchymal effects needs further study.
Similarly, although there is debate on whether there is an
increased risk for stroke in patients with the prothrombin
G20210A gene mutation (which results in increased con-
centrations of plasma prothrombin; Wu and Tsongalis 2001),
the question of whether this mutation might increase the
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severity of a stroke by increasing brain thrombin concentra-
tions has not been examined.
High concentrations of thrombin are required to kill
neurons and astrocytes in vitro. Thus, for example, 5 U/mL
induces cell death in mixed neuronal/astrocyte cultures (Jiang
et al. 2002a). It should be noted, however, that much lower
concentrations of thrombin may cause cell death in stressed
cells. Weinstein et al. examining Ad12 HER 10 cells, found
that thrombin concentrations as low as 1.2 · 10)3 U/mL
caused cell death in hypoglycemic (0.1 mM glucose) but not
in normoglycemic conditions (Weinstein et al. 1998). This
suggests that thrombin might cause brain injury even at very
low levels during cerebral ischemia. Indeed, small doses of
exogenous thrombin exacerbate ischemic brain injury in vivo
(Xi et al. 2002).
Thrombin may cause brain injury by enhancing excito-
toxicity, activating gelatinases and stimulating cytokine
release. Glutamate-induced excitotoxicity is an important
mechanism in ischemic brain injury, at least in animals. For
example, MK 801, an NMDA antagonist, reduces infarct size
after focal cerebral ischemia in the rat. Activation of PAR-1
potentiates NMDA receptor responses in CA1 pyramidal
cells and the effect of thrombin can be mimicked by TRAP.
Thrombin-induced NMDA receptor potentiation is reduced
in PAR-1 knockout mice (Gingrich et al. 2000).
Thrombin activates gelatinase A (also called matrix met-
alloproteinases-2, MMP-2) in endothelial cells (Nguyen
et al. 1999). MMPs are members of a family of zinc-
dependent proteases that can degrade extracellular matrix and
cause BBB disruption.
Thrombin signaling pathways in brain injury
and induced brain tolerance
The fact that thrombin can reduce brain injury at low
concentrations and enhance it at high concentrations raises
the question of whether these effects are mediated by either
the activation of different pathways or the differential
stimulation of the same pathway? For example, protection
and damage might result from stimulation of receptor and
non-receptor mediated pathways or activation of different
receptors. Alternately, whether thrombin causes brain injury
or brain protection may depend on the extent to which one
type of receptor is activated. Although this question has not
been definitively answered, there is evidence that thrombin-
induced brain tolerance and thrombin-mediated brain damage
may share the same initial signaling pathway involving
activation of thrombin receptors (Donovan and Cunningham
1998).
Prior studies have implicated several different signaling
cascades induced by thrombin receptor activation including
activation of Ras and Rho, stimulation of MAPKs phos-
phorylation and release of intracellular calcium (Grand et al.
1996; Ubl and Reiser 1997; Dery et al. 1998; Donovan and
Cunningham 1998; Xi et al. 2001). Thrombin is able to
activate Ras (an 189 amino acid peptide) and increases RhoA
(a small GTP-binding protein) activity (Dery et al. 1998;
Donovan and Cunningham 1998). RhoA activity increases in
neurons and astrocytes in vitro after thrombin stimulation
and exoenzyme C3 (RhoA inhibitor) blocks thrombin-
induced cell death and thrombin-induced protection against
hypoglycemia (Donovan et al. 1997; Donovan and Cun-
ningham 1998).
MAPKs are well-known cytoplasmatic signal transducers
with an important role in thrombin-induced brain tolerance.
In vivo, p44/42 MAPKs are activated in the brain after
intracerebral infusion of thrombin. PD98059, a specific p44/
42 MAPKs kinase inhibitor, abolished thrombin-induced
activation of p44/42 MAPKs and also blocked thrombin-
induced brain tolerance (Xi et al. 2001). In vitro, thrombin
treatment also activated p44/42 MAPKs and PD98059
completely blocked the cytoprotective effect of thrombin
pretreatment, indicating that the p44/42 MAPK system
mediates the neuroprotective effect induced by thrombin
(Jiang et al. 2002a).
Calcium mobilization into the cell is related to thrombin
signaling. Thrombin stimulates IP3. IP3 then regulates
intracellular calcium content (Dery et al. 1998). Both
thrombin and thrombin receptor activating peptide can
stimulate calcium signaling in astrocytes (Ubl et al. 2000).
In cultured hippocampal slices, Striggow et al. found that
50 pM thrombin induces repetitive intracellular calcium
spikes and is neuroprotective against oxygen and glucose
deprivation. In contrast, 500 pM thrombin causes a delayed
single calcium spike and is not neuroprotective (Striggow
et al. 2000).
Recently, we and others have found that hypoxia inducible
factor-1a (HIF-1a) may be regulated by thrombin. Intracer-
ebral infusion of thrombin up-regulates HIF-1a protein levels
in neurons. This effect appears to be specific, as it was
blocked by a co-infusion of hirudin. HIF-1a protein levels
increased without changing HIF-1a messenger RNA levels,
indicating that thrombin up-regulates HIF-1a by reducing
HIF-1a degradation (Jiang et al. 2002b). The thrombin effect
is not likely to be mediated by hypoxia as we have previously
found no reduction in cerebral blood flow after thrombin
injections into the basal ganglia (Lee et al. 1997b). Other
studies also found that HIF-1a levels are up-regulated in
vascular smooth muscle cells by thrombin (Richard et al.
2000). In addition, the experiments of Richard et al. indicate
that HIF-1a can be phosphorylated by p44/42 MAPKs and
thrombin induces HIF-1a up-regulation without a change of
oxygen level (Richard et al. 2000).
HIF-1a regulates the expression of a number of genes,
including PAI-1 and heme oxygenase-1 (HO-1). The serpin
PAI-1 is up-regulated by thrombin and may be neuroprotec-
tive, perhaps via its ability to inhibit thrombin and/or other
serine proteases (Hua et al. 2002). HO-1, also known as
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HSP32, degrades heme into iron, carbon monoxide and
biliverdin. Studies suggest that HO-1 is involved in
cytoprotection from different kinds of injuries, although
HO-1 up-regulation may induce brain injury by increasing
cellular iron content (Sharp et al. 1999). In common with
thrombin, HIF-1a and HO-1 have implicated in both
reducing and enhancing brain injury. The question of
whether there is some adaptive advantage to the latter (e.g.
the removal of dysfunctional cells) in some forms of injury,
has yet to be answered.
Thus, in summary, thrombin acting on thrombin receptors
at low concentration induces neuroprotection and at high
concentration causes brain injury. Multi-signal transduction
pathways are involved. Modulating thrombin activity and its
inhibitors in the brain may establish novel therapeutic
strategies for ischemic, hemorrhagic and traumatic brain
injury. However, because of the dichotomy in the effects of
thrombin on brain injury, it is essential to delineate the
pathways involved in both the deleterious and the beneficial
effects of thrombin on brain injury. Selective inhibition of the
former is likely to prove a more effective therapeutic strategy
than a direct thrombin inhibitor. The current availability of
PAR-1, -3 and -4 knockout mice should greatly facilitate this
process.
In addition, there is still the largely unanswered question
as to what is the normal function of prothrombin, thrombin
and thrombin receptors in the brain. Is there a role limited to
situations of brain injury? Or, as has been proposed for tPA
(Seeds et al. 1995), do they have a role in normal brain
function such as brain plasticity? Evidence on their effects on
astrocyte and neuron morphology and ion channel activity
(Grand et al. 1996), suggests that this may be the case.
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